KYTHERA Biopharmaceuticals Inc., one of our stock picks of June 2013, is now set to be acquired by Allergan in a cash and equity transaction valued at $75 per share. KYTH was trading around $22 when we alerted our premium subscribers to the stock on June 6, 2013. Had you bought the stock then, you would have made a gain of more than 235% based on the per share consideration.